SlideShare a Scribd company logo
Insilico  methods  for design of novel inhibitors of  Human leukocyte  elastase by L. Jayashankar, M.Tech Pharma., GVK Biosciences, Hyderabad. (Contributed oral paper in ICSCI-2006)
The possible ways of drug design ,[object Object],[object Object]
Stages in Drug Discovery
Identify disease state Relevant biomolecular target Assay Development e.g. Receptor cloning and expression Compound Collections Primary Assay (high through-put, usually  in vitro ) Secondary Assays (counter screens, bioavailability, toxicity, metabolism, etc.., usually  in vivo ) Bioinformatics Protein Modeling Drug Discovery and Design Clinical Candidate Lead compounds and SAR Chemical Synthesis Design Mapping Fitting In Silico
 
Raw data X-ray NMR Homology Target definition via Structure determination and prediction
Get the diffraction pattern Phasing : MIR and molecular replacement Electron density map Refinement Fit sequence to density X-ray based Target Definition
Ligand design   When the structure of an enzyme is known,  It is possible to display in a modeling environment  ( Insight II ) to select potential binding sites by inspection  and to  design an inhibitor that targets those sites.
De Novo (New) Ligand Design  They analyze the properties of the active site  Determine favorable-binding locations for individual atoms or small fragments.  Although conceptually simple, these approaches are quite useful for successful ligand design.
[object Object],[object Object],[object Object],[object Object],Human Leukocyte Elastase
[object Object],[object Object],[object Object]
[object Object]
 
 
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object]
Ramchandran plot for 1 EAS
[object Object],[object Object]
Site Search  Aim: To find  all cavities inside a protein   Protein is mapped on a grid.  One must visually inspect, select, adjust and define the binding site.
Ligand based drug designing ,[object Object],[object Object],[object Object]
. . . . . . Log P Log 1/C Y X Draw best possible lines through the data points on the graph
Best line will be the one close to the data points To measure how close the data points are vertical lines are drawn from each point These verticals are measured and then scored in order to eliminate the negative values Squares are then added up to give a total Best line through the points will be the line where the total is a minimum
The significance of the equation is know as regression coefficient(r) For a perfect fit  r2=1 Good fit generally have r2 values of 0.95 or above Physiochemical properties Most commonly studied are Hydrophobic,Electrostatic and steric interaction Hydrophobic properties can easily quantified for complete molecules or for individual substituents
Electronic and steric properties are more difficult to quantify,and quantifications are only feasible for individual substituents QSAR studies are being carried out on compounds of the same general structure where substituents on aromatic rings or accessible functional groups are varied QSAR studies then considers how the hydrophobic,electronic,and steric properties of the substituents affect the biological activity
Hydrophobicity How easily it crosses the cell membranes and may well also be important in receptor interactions Changing substituents on a drug may well have significant effects on its hydrophobic character and hence its biological activity P=  Concentration of the drug in octonol Concentration of drug in aqueous solution
Hydrophobic compounds - P-values  hydrophilic compounds  - low P values Biological activity  =  1/C C=Concentration of the drug required to achieve a defined level of biological activity If Log P values is resticted to a small range (1-4) a straight line graph is obtained showing that there is a relation ship between hydrophobicity and biological activity Log(1/C)=K1 log P+k2
Increasing the hydrophobicity of a lead compound results in a increase in biological activity Compounds having a log P value close to 2 should be capable of entering the central nervous system effectively Drugs which are designed to act elsewhere in the body should have lop values significantly different from 2 in order to avoid possible central nervous system
Substituent Hydrophobicity constant Measure of how hydrophobic a substituent is relative to hydrogen πx  = log Px  -  log PH PH-partition coefficient of a standard compound Px-partition coefficient of a standard compound with substituent +value –Substituent is more hydrophobic -value  - Substituent is less hydrophobic
The electronic effects of various substituents will clearly have an effect on drugs ionisation or polarity Measured in terms of Hammet substituent constant  σ σ-measure of electronic with drawing or electron donating ability of a substituent  Determined by measuring the ability of a series of substituted benzoic acids compared to the dissociation of benzoic acid itself Cl, CN, CF3 –σ values positive (Electron withdrawing) Me ethyl and butyl – σ –values (electron donating) Values also depend whether the subsituent is meta or or para
σ values cant be measured for ortho substituents since  such substituents have an important steric as well as electronic effects Electron withdrawing groups increase the rate of hydrolysis and have positive values Steric properties Bulk ,size,and shape of the drug may have influence  on this process Tafts steric factor Molar refractivity-measure of volume occupied by an atom or group of atoms
[object Object],[object Object],[object Object],QSAR
[object Object],[object Object],[object Object]
 
Grid search
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
Typical QSAR study table
[object Object],[object Object]
[object Object],[object Object]
[object Object]
[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object]
Comparision of different statistical analysis r^2=correlation coefficient .856 .739 2 .798 .013 9.26 .910 .839 2 .795 .0168 6.26 .839 .793 2 .845 .002 10.56 R^2  XVR^2  Outliers  BSR^2  BSR^2ERROR  PRESS 2D QSAR RSA MFA Statistical parameters
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Flexible docking based on fragmentation ,[object Object],[object Object],[object Object],[object Object],[object Object]
Docking by simulation ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
Pretein scffold with ligand docked at active site
The docked molecule in space filled model Ligand
Docking scores of the ligand in the active site of human leukocyte elastase
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
LIGAND  INTERACTING WITH THE STATED AMINOACIDS IN THE ACTIVE SITE
[object Object],[object Object],Affinity
Results and discussion ,[object Object],[object Object],[object Object]

More Related Content

What's hot

Drug design and discovery ppt
Drug design and discovery pptDrug design and discovery ppt
Drug design and discovery ppt
Dr NEETHU ASOKAN
 
Basics of QSAR Modeling
Basics of QSAR ModelingBasics of QSAR Modeling
Basics of QSAR Modeling
Prachi Pradeep
 
De Novo Drug Design
De Novo Drug DesignDe Novo Drug Design
De Novo Drug Design
MAYANK ,MEHENDIRATTA
 
Pharmacophore
PharmacophorePharmacophore
Pharmacophoreirecen
 
Lecture 4 ligand based drug design
Lecture 4 ligand based drug designLecture 4 ligand based drug design
Lecture 4 ligand based drug design
RAJAN ROLTA
 
CADD
CADDCADD
Virtual Screening in Drug Discovery
Virtual Screening in Drug DiscoveryVirtual Screening in Drug Discovery
Virtual Screening in Drug Discovery
Abhik Seal
 
pharmacophore mapping
pharmacophore mapping pharmacophore mapping
pharmacophore mapping
ashutosh mahale
 
Virtual sreening
Virtual sreeningVirtual sreening
Virtual sreening
Mahendra G S
 
Pharmacophore mapping in Drug Development
Pharmacophore mapping in Drug DevelopmentPharmacophore mapping in Drug Development
Pharmacophore mapping in Drug Development
Mbachu Chinedu
 
PHARMACOHORE MAPPING AND VIRTUAL SCRRENING FOR RESEARCH DEPARTMENT
PHARMACOHORE MAPPING AND VIRTUAL SCRRENING FOR RESEARCH DEPARTMENTPHARMACOHORE MAPPING AND VIRTUAL SCRRENING FOR RESEARCH DEPARTMENT
PHARMACOHORE MAPPING AND VIRTUAL SCRRENING FOR RESEARCH DEPARTMENT
Shikha Popali
 
Molecular modeling in drug design
Molecular modeling in drug designMolecular modeling in drug design
threading and homology modelling methods
threading and homology modelling methodsthreading and homology modelling methods
threading and homology modelling methods
mohammed muzammil
 
Presentation on concept of pharmacophore mapping and pharmacophore based scre...
Presentation on concept of pharmacophore mapping and pharmacophore based scre...Presentation on concept of pharmacophore mapping and pharmacophore based scre...
Presentation on concept of pharmacophore mapping and pharmacophore based scre...
B V V S Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote
 
3d qsar
3d qsar3d qsar
3d qsar
Mahendra G S
 
molecular docking its types and de novo drug design and application and softw...
molecular docking its types and de novo drug design and application and softw...molecular docking its types and de novo drug design and application and softw...
molecular docking its types and de novo drug design and application and softw...
GAUTAM KHUNE
 
3D QSAR
3D QSAR3D QSAR
3D QSAR
suraj wanjari
 
De novo drug design
De novo drug designDe novo drug design
De novo drug design
mojdeh y
 

What's hot (20)

Drug design and discovery ppt
Drug design and discovery pptDrug design and discovery ppt
Drug design and discovery ppt
 
Basics of QSAR Modeling
Basics of QSAR ModelingBasics of QSAR Modeling
Basics of QSAR Modeling
 
De Novo Drug Design
De Novo Drug DesignDe Novo Drug Design
De Novo Drug Design
 
Pharmacophore
PharmacophorePharmacophore
Pharmacophore
 
Lecture 4 ligand based drug design
Lecture 4 ligand based drug designLecture 4 ligand based drug design
Lecture 4 ligand based drug design
 
CADD
CADDCADD
CADD
 
Virtual Screening in Drug Discovery
Virtual Screening in Drug DiscoveryVirtual Screening in Drug Discovery
Virtual Screening in Drug Discovery
 
pharmacophore mapping
pharmacophore mapping pharmacophore mapping
pharmacophore mapping
 
Virtual sreening
Virtual sreeningVirtual sreening
Virtual sreening
 
Pharmacophore mapping in Drug Development
Pharmacophore mapping in Drug DevelopmentPharmacophore mapping in Drug Development
Pharmacophore mapping in Drug Development
 
PHARMACOHORE MAPPING AND VIRTUAL SCRRENING FOR RESEARCH DEPARTMENT
PHARMACOHORE MAPPING AND VIRTUAL SCRRENING FOR RESEARCH DEPARTMENTPHARMACOHORE MAPPING AND VIRTUAL SCRRENING FOR RESEARCH DEPARTMENT
PHARMACOHORE MAPPING AND VIRTUAL SCRRENING FOR RESEARCH DEPARTMENT
 
Drug design
Drug designDrug design
Drug design
 
Molecular modeling in drug design
Molecular modeling in drug designMolecular modeling in drug design
Molecular modeling in drug design
 
threading and homology modelling methods
threading and homology modelling methodsthreading and homology modelling methods
threading and homology modelling methods
 
Presentation on concept of pharmacophore mapping and pharmacophore based scre...
Presentation on concept of pharmacophore mapping and pharmacophore based scre...Presentation on concept of pharmacophore mapping and pharmacophore based scre...
Presentation on concept of pharmacophore mapping and pharmacophore based scre...
 
3d qsar
3d qsar3d qsar
3d qsar
 
molecular docking its types and de novo drug design and application and softw...
molecular docking its types and de novo drug design and application and softw...molecular docking its types and de novo drug design and application and softw...
molecular docking its types and de novo drug design and application and softw...
 
Computer aided Drug designing (CADD)
Computer aided Drug designing (CADD)Computer aided Drug designing (CADD)
Computer aided Drug designing (CADD)
 
3D QSAR
3D QSAR3D QSAR
3D QSAR
 
De novo drug design
De novo drug designDe novo drug design
De novo drug design
 

Viewers also liked

In Silico Drug Designing
In Silico Drug Designing In Silico Drug Designing
In Silico Drug Designing
PALWINDER GILL
 
VLife SCOPE for Lead Optimization
VLife SCOPE for Lead OptimizationVLife SCOPE for Lead Optimization
VLife SCOPE for Lead Optimization
VLife Sciences Tech. Pvt. Ltd.
 
PERL- Bioperl modules
PERL- Bioperl modulesPERL- Bioperl modules
PERL- Bioperl modules
Nixon Mendez
 
Stability of protein drugs
Stability of protein drugsStability of protein drugs
Stability of protein drugs
Zahir Khan
 
Interaction fingerprint: 1D representation of 3D protein-ligand complexes
Interaction fingerprint: 1D representation of 3D protein-ligand complexesInteraction fingerprint: 1D representation of 3D protein-ligand complexes
Interaction fingerprint: 1D representation of 3D protein-ligand complexes
Vladimir Chupakhin
 
Bioinformatics and BioPerl
Bioinformatics and BioPerlBioinformatics and BioPerl
Bioinformatics and BioPerl
Jason Stajich
 
Biological databases
Biological databasesBiological databases
Biological databases
Sucheta Tripathy
 
Insilico Analysis towards Infuenza Virus- A Homology modelling and molecular ...
Insilico Analysis towards Infuenza Virus- A Homology modelling and molecular ...Insilico Analysis towards Infuenza Virus- A Homology modelling and molecular ...
Insilico Analysis towards Infuenza Virus- A Homology modelling and molecular ...
Subhasree Pal
 
CADD Lecture
CADD LectureCADD Lecture
CADD Lecture
ksrahmangt
 
protein stability
protein stabilityprotein stability
protein stability
Deepak Rohilla
 
Biological Databases
Biological DatabasesBiological Databases
Biological Databases
Shweta Kagliwal
 
Lecture1 1 Perl for bioinformatics Davide Pisani & James Cotton
Lecture1 1 Perl for bioinformatics Davide Pisani & James CottonLecture1 1 Perl for bioinformatics Davide Pisani & James Cotton
Lecture1 1 Perl for bioinformatics Davide Pisani & James Cotton
nathanlawless
 
Protein-Ligand Docking
Protein-Ligand DockingProtein-Ligand Docking
Protein-Ligand Dockingbaoilleach
 
Biological databases
Biological databasesBiological databases
Biological databases
Malla Reddy College of Pharmacy
 
Computer aided drug designing
Computer aided drug designingComputer aided drug designing
Computer aided drug designing
Muhammed sadiq
 
Protein docking
Protein dockingProtein docking
Protein docking
Senthil Natesan
 
Gentic code
Gentic codeGentic code
Gentic code
nazish66
 

Viewers also liked (20)

In Silico Drug Designing
In Silico Drug Designing In Silico Drug Designing
In Silico Drug Designing
 
VLife SCOPE for Lead Optimization
VLife SCOPE for Lead OptimizationVLife SCOPE for Lead Optimization
VLife SCOPE for Lead Optimization
 
PERL- Bioperl modules
PERL- Bioperl modulesPERL- Bioperl modules
PERL- Bioperl modules
 
Stability of protein drugs
Stability of protein drugsStability of protein drugs
Stability of protein drugs
 
Interaction fingerprint: 1D representation of 3D protein-ligand complexes
Interaction fingerprint: 1D representation of 3D protein-ligand complexesInteraction fingerprint: 1D representation of 3D protein-ligand complexes
Interaction fingerprint: 1D representation of 3D protein-ligand complexes
 
Bioinformatics and BioPerl
Bioinformatics and BioPerlBioinformatics and BioPerl
Bioinformatics and BioPerl
 
Gene and genetic code
Gene and genetic codeGene and genetic code
Gene and genetic code
 
Biological databases
Biological databasesBiological databases
Biological databases
 
Insilico Analysis towards Infuenza Virus- A Homology modelling and molecular ...
Insilico Analysis towards Infuenza Virus- A Homology modelling and molecular ...Insilico Analysis towards Infuenza Virus- A Homology modelling and molecular ...
Insilico Analysis towards Infuenza Virus- A Homology modelling and molecular ...
 
CADD Lecture
CADD LectureCADD Lecture
CADD Lecture
 
protein stability
protein stabilityprotein stability
protein stability
 
Biological Databases
Biological DatabasesBiological Databases
Biological Databases
 
Genetic code
Genetic codeGenetic code
Genetic code
 
Lecture1 1 Perl for bioinformatics Davide Pisani & James Cotton
Lecture1 1 Perl for bioinformatics Davide Pisani & James CottonLecture1 1 Perl for bioinformatics Davide Pisani & James Cotton
Lecture1 1 Perl for bioinformatics Davide Pisani & James Cotton
 
Protein-Ligand Docking
Protein-Ligand DockingProtein-Ligand Docking
Protein-Ligand Docking
 
Qsar
QsarQsar
Qsar
 
Biological databases
Biological databasesBiological databases
Biological databases
 
Computer aided drug designing
Computer aided drug designingComputer aided drug designing
Computer aided drug designing
 
Protein docking
Protein dockingProtein docking
Protein docking
 
Gentic code
Gentic codeGentic code
Gentic code
 

Similar to Insilico methods for design of novel inhibitors of Human leukocyte elastase

Physicochemical properties (descriptors) in QSAR.pdf
Physicochemical properties (descriptors) in QSAR.pdfPhysicochemical properties (descriptors) in QSAR.pdf
Physicochemical properties (descriptors) in QSAR.pdf
RAJ K. MAURYA
 
E0362430
E0362430E0362430
E0362430
IOSR Journals
 
Qsar ppt
Qsar pptQsar ppt
Quantitative Structure Activity Relationship.pptx
Quantitative Structure Activity Relationship.pptxQuantitative Structure Activity Relationship.pptx
Quantitative Structure Activity Relationship.pptx
RadhaChafle1
 
Introduction to Drug Design
 Introduction to Drug Design Introduction to Drug Design
Introduction to Drug Design
Sagar Magar
 
Quantative Structure-Activity Relationships (QSAR)
Quantative Structure-Activity Relationships (QSAR)Quantative Structure-Activity Relationships (QSAR)
Quantative Structure-Activity Relationships (QSAR)Atai Rabby
 
QSAR.pptx
QSAR.pptxQSAR.pptx
QSAR.pptx
QSAR.pptxQSAR.pptx
Introduction to OECD QSAR Toolbox
Introduction to OECD QSAR ToolboxIntroduction to OECD QSAR Toolbox
Introduction to OECD QSAR Toolboxguestcfca1eb1
 
Lecture5 100717171918-phpapp01
Lecture5 100717171918-phpapp01Lecture5 100717171918-phpapp01
Lecture5 100717171918-phpapp01
Cleophas Rwemera
 
QSAR Studies presentation
 QSAR Studies presentation QSAR Studies presentation
QSAR Studies presentation
Ashruti agrawal
 
consensus superiority of the pharmacophore based alignment, over maximum comm...
consensus superiority of the pharmacophore based alignment, over maximum comm...consensus superiority of the pharmacophore based alignment, over maximum comm...
consensus superiority of the pharmacophore based alignment, over maximum comm...
Deepak Rohilla
 
Qsar UMA
Qsar   UMAQsar   UMA
Qsar UMA
Uma Bansal
 
QSAR
QSARQSAR
Metabolomics.ppt molecular biology ( botany)
Metabolomics.ppt molecular biology ( botany)Metabolomics.ppt molecular biology ( botany)
Metabolomics.ppt molecular biology ( botany)
Umehabiba502674
 
Qsar by hansch analysis
Qsar by hansch analysisQsar by hansch analysis
Qsar by hansch analysis
Pharma Rising, Bhopal
 
QSAR by hansch analysis
QSAR by hansch analysisQSAR by hansch analysis
QSAR by hansch analysis
kholood adil
 

Similar to Insilico methods for design of novel inhibitors of Human leukocyte elastase (20)

Physicochemical properties (descriptors) in QSAR.pdf
Physicochemical properties (descriptors) in QSAR.pdfPhysicochemical properties (descriptors) in QSAR.pdf
Physicochemical properties (descriptors) in QSAR.pdf
 
E0362430
E0362430E0362430
E0362430
 
Lecture 6
Lecture 6Lecture 6
Lecture 6
 
Qsar ppt
Qsar pptQsar ppt
Qsar ppt
 
Lecture 5
Lecture 5Lecture 5
Lecture 5
 
Quantitative Structure Activity Relationship.pptx
Quantitative Structure Activity Relationship.pptxQuantitative Structure Activity Relationship.pptx
Quantitative Structure Activity Relationship.pptx
 
QSAR.pptx
QSAR.pptxQSAR.pptx
QSAR.pptx
 
Introduction to Drug Design
 Introduction to Drug Design Introduction to Drug Design
Introduction to Drug Design
 
Quantative Structure-Activity Relationships (QSAR)
Quantative Structure-Activity Relationships (QSAR)Quantative Structure-Activity Relationships (QSAR)
Quantative Structure-Activity Relationships (QSAR)
 
QSAR.pptx
QSAR.pptxQSAR.pptx
QSAR.pptx
 
QSAR.pptx
QSAR.pptxQSAR.pptx
QSAR.pptx
 
Introduction to OECD QSAR Toolbox
Introduction to OECD QSAR ToolboxIntroduction to OECD QSAR Toolbox
Introduction to OECD QSAR Toolbox
 
Lecture5 100717171918-phpapp01
Lecture5 100717171918-phpapp01Lecture5 100717171918-phpapp01
Lecture5 100717171918-phpapp01
 
QSAR Studies presentation
 QSAR Studies presentation QSAR Studies presentation
QSAR Studies presentation
 
consensus superiority of the pharmacophore based alignment, over maximum comm...
consensus superiority of the pharmacophore based alignment, over maximum comm...consensus superiority of the pharmacophore based alignment, over maximum comm...
consensus superiority of the pharmacophore based alignment, over maximum comm...
 
Qsar UMA
Qsar   UMAQsar   UMA
Qsar UMA
 
QSAR
QSARQSAR
QSAR
 
Metabolomics.ppt molecular biology ( botany)
Metabolomics.ppt molecular biology ( botany)Metabolomics.ppt molecular biology ( botany)
Metabolomics.ppt molecular biology ( botany)
 
Qsar by hansch analysis
Qsar by hansch analysisQsar by hansch analysis
Qsar by hansch analysis
 
QSAR by hansch analysis
QSAR by hansch analysisQSAR by hansch analysis
QSAR by hansch analysis
 

Recently uploaded

PCI PIN Basics Webinar from the Controlcase Team
PCI PIN Basics Webinar from the Controlcase TeamPCI PIN Basics Webinar from the Controlcase Team
PCI PIN Basics Webinar from the Controlcase Team
ControlCase
 
Unsubscribed: Combat Subscription Fatigue With a Membership Mentality by Head...
Unsubscribed: Combat Subscription Fatigue With a Membership Mentality by Head...Unsubscribed: Combat Subscription Fatigue With a Membership Mentality by Head...
Unsubscribed: Combat Subscription Fatigue With a Membership Mentality by Head...
Product School
 
From Daily Decisions to Bottom Line: Connecting Product Work to Revenue by VP...
From Daily Decisions to Bottom Line: Connecting Product Work to Revenue by VP...From Daily Decisions to Bottom Line: Connecting Product Work to Revenue by VP...
From Daily Decisions to Bottom Line: Connecting Product Work to Revenue by VP...
Product School
 
Accelerate your Kubernetes clusters with Varnish Caching
Accelerate your Kubernetes clusters with Varnish CachingAccelerate your Kubernetes clusters with Varnish Caching
Accelerate your Kubernetes clusters with Varnish Caching
Thijs Feryn
 
UiPath Test Automation using UiPath Test Suite series, part 4
UiPath Test Automation using UiPath Test Suite series, part 4UiPath Test Automation using UiPath Test Suite series, part 4
UiPath Test Automation using UiPath Test Suite series, part 4
DianaGray10
 
Connector Corner: Automate dynamic content and events by pushing a button
Connector Corner: Automate dynamic content and events by pushing a buttonConnector Corner: Automate dynamic content and events by pushing a button
Connector Corner: Automate dynamic content and events by pushing a button
DianaGray10
 
Mission to Decommission: Importance of Decommissioning Products to Increase E...
Mission to Decommission: Importance of Decommissioning Products to Increase E...Mission to Decommission: Importance of Decommissioning Products to Increase E...
Mission to Decommission: Importance of Decommissioning Products to Increase E...
Product School
 
How world-class product teams are winning in the AI era by CEO and Founder, P...
How world-class product teams are winning in the AI era by CEO and Founder, P...How world-class product teams are winning in the AI era by CEO and Founder, P...
How world-class product teams are winning in the AI era by CEO and Founder, P...
Product School
 
Elevating Tactical DDD Patterns Through Object Calisthenics
Elevating Tactical DDD Patterns Through Object CalisthenicsElevating Tactical DDD Patterns Through Object Calisthenics
Elevating Tactical DDD Patterns Through Object Calisthenics
Dorra BARTAGUIZ
 
Transcript: Selling digital books in 2024: Insights from industry leaders - T...
Transcript: Selling digital books in 2024: Insights from industry leaders - T...Transcript: Selling digital books in 2024: Insights from industry leaders - T...
Transcript: Selling digital books in 2024: Insights from industry leaders - T...
BookNet Canada
 
Leading Change strategies and insights for effective change management pdf 1.pdf
Leading Change strategies and insights for effective change management pdf 1.pdfLeading Change strategies and insights for effective change management pdf 1.pdf
Leading Change strategies and insights for effective change management pdf 1.pdf
OnBoard
 
AI for Every Business: Unlocking Your Product's Universal Potential by VP of ...
AI for Every Business: Unlocking Your Product's Universal Potential by VP of ...AI for Every Business: Unlocking Your Product's Universal Potential by VP of ...
AI for Every Business: Unlocking Your Product's Universal Potential by VP of ...
Product School
 
FIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance Osaka Seminar: Overview.pdfFIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance
 
When stars align: studies in data quality, knowledge graphs, and machine lear...
When stars align: studies in data quality, knowledge graphs, and machine lear...When stars align: studies in data quality, knowledge graphs, and machine lear...
When stars align: studies in data quality, knowledge graphs, and machine lear...
Elena Simperl
 
Key Trends Shaping the Future of Infrastructure.pdf
Key Trends Shaping the Future of Infrastructure.pdfKey Trends Shaping the Future of Infrastructure.pdf
Key Trends Shaping the Future of Infrastructure.pdf
Cheryl Hung
 
Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...
Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...
Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...
Jeffrey Haguewood
 
Epistemic Interaction - tuning interfaces to provide information for AI support
Epistemic Interaction - tuning interfaces to provide information for AI supportEpistemic Interaction - tuning interfaces to provide information for AI support
Epistemic Interaction - tuning interfaces to provide information for AI support
Alan Dix
 
Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...
Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...
Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...
Ramesh Iyer
 
FIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdf
FIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdfFIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdf
FIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdf
FIDO Alliance
 
LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...
LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...
LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...
DanBrown980551
 

Recently uploaded (20)

PCI PIN Basics Webinar from the Controlcase Team
PCI PIN Basics Webinar from the Controlcase TeamPCI PIN Basics Webinar from the Controlcase Team
PCI PIN Basics Webinar from the Controlcase Team
 
Unsubscribed: Combat Subscription Fatigue With a Membership Mentality by Head...
Unsubscribed: Combat Subscription Fatigue With a Membership Mentality by Head...Unsubscribed: Combat Subscription Fatigue With a Membership Mentality by Head...
Unsubscribed: Combat Subscription Fatigue With a Membership Mentality by Head...
 
From Daily Decisions to Bottom Line: Connecting Product Work to Revenue by VP...
From Daily Decisions to Bottom Line: Connecting Product Work to Revenue by VP...From Daily Decisions to Bottom Line: Connecting Product Work to Revenue by VP...
From Daily Decisions to Bottom Line: Connecting Product Work to Revenue by VP...
 
Accelerate your Kubernetes clusters with Varnish Caching
Accelerate your Kubernetes clusters with Varnish CachingAccelerate your Kubernetes clusters with Varnish Caching
Accelerate your Kubernetes clusters with Varnish Caching
 
UiPath Test Automation using UiPath Test Suite series, part 4
UiPath Test Automation using UiPath Test Suite series, part 4UiPath Test Automation using UiPath Test Suite series, part 4
UiPath Test Automation using UiPath Test Suite series, part 4
 
Connector Corner: Automate dynamic content and events by pushing a button
Connector Corner: Automate dynamic content and events by pushing a buttonConnector Corner: Automate dynamic content and events by pushing a button
Connector Corner: Automate dynamic content and events by pushing a button
 
Mission to Decommission: Importance of Decommissioning Products to Increase E...
Mission to Decommission: Importance of Decommissioning Products to Increase E...Mission to Decommission: Importance of Decommissioning Products to Increase E...
Mission to Decommission: Importance of Decommissioning Products to Increase E...
 
How world-class product teams are winning in the AI era by CEO and Founder, P...
How world-class product teams are winning in the AI era by CEO and Founder, P...How world-class product teams are winning in the AI era by CEO and Founder, P...
How world-class product teams are winning in the AI era by CEO and Founder, P...
 
Elevating Tactical DDD Patterns Through Object Calisthenics
Elevating Tactical DDD Patterns Through Object CalisthenicsElevating Tactical DDD Patterns Through Object Calisthenics
Elevating Tactical DDD Patterns Through Object Calisthenics
 
Transcript: Selling digital books in 2024: Insights from industry leaders - T...
Transcript: Selling digital books in 2024: Insights from industry leaders - T...Transcript: Selling digital books in 2024: Insights from industry leaders - T...
Transcript: Selling digital books in 2024: Insights from industry leaders - T...
 
Leading Change strategies and insights for effective change management pdf 1.pdf
Leading Change strategies and insights for effective change management pdf 1.pdfLeading Change strategies and insights for effective change management pdf 1.pdf
Leading Change strategies and insights for effective change management pdf 1.pdf
 
AI for Every Business: Unlocking Your Product's Universal Potential by VP of ...
AI for Every Business: Unlocking Your Product's Universal Potential by VP of ...AI for Every Business: Unlocking Your Product's Universal Potential by VP of ...
AI for Every Business: Unlocking Your Product's Universal Potential by VP of ...
 
FIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance Osaka Seminar: Overview.pdfFIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance Osaka Seminar: Overview.pdf
 
When stars align: studies in data quality, knowledge graphs, and machine lear...
When stars align: studies in data quality, knowledge graphs, and machine lear...When stars align: studies in data quality, knowledge graphs, and machine lear...
When stars align: studies in data quality, knowledge graphs, and machine lear...
 
Key Trends Shaping the Future of Infrastructure.pdf
Key Trends Shaping the Future of Infrastructure.pdfKey Trends Shaping the Future of Infrastructure.pdf
Key Trends Shaping the Future of Infrastructure.pdf
 
Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...
Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...
Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...
 
Epistemic Interaction - tuning interfaces to provide information for AI support
Epistemic Interaction - tuning interfaces to provide information for AI supportEpistemic Interaction - tuning interfaces to provide information for AI support
Epistemic Interaction - tuning interfaces to provide information for AI support
 
Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...
Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...
Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...
 
FIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdf
FIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdfFIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdf
FIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdf
 
LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...
LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...
LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...
 

Insilico methods for design of novel inhibitors of Human leukocyte elastase

  • 1. Insilico methods for design of novel inhibitors of Human leukocyte elastase by L. Jayashankar, M.Tech Pharma., GVK Biosciences, Hyderabad. (Contributed oral paper in ICSCI-2006)
  • 2.
  • 3. Stages in Drug Discovery
  • 4. Identify disease state Relevant biomolecular target Assay Development e.g. Receptor cloning and expression Compound Collections Primary Assay (high through-put, usually in vitro ) Secondary Assays (counter screens, bioavailability, toxicity, metabolism, etc.., usually in vivo ) Bioinformatics Protein Modeling Drug Discovery and Design Clinical Candidate Lead compounds and SAR Chemical Synthesis Design Mapping Fitting In Silico
  • 5.  
  • 6. Raw data X-ray NMR Homology Target definition via Structure determination and prediction
  • 7. Get the diffraction pattern Phasing : MIR and molecular replacement Electron density map Refinement Fit sequence to density X-ray based Target Definition
  • 8. Ligand design When the structure of an enzyme is known, It is possible to display in a modeling environment ( Insight II ) to select potential binding sites by inspection and to design an inhibitor that targets those sites.
  • 9. De Novo (New) Ligand Design They analyze the properties of the active site Determine favorable-binding locations for individual atoms or small fragments. Although conceptually simple, these approaches are quite useful for successful ligand design.
  • 10.
  • 11.
  • 12.
  • 13.  
  • 14.  
  • 15.
  • 16.
  • 17.
  • 19.
  • 20. Site Search Aim: To find all cavities inside a protein Protein is mapped on a grid. One must visually inspect, select, adjust and define the binding site.
  • 21.
  • 22. . . . . . . Log P Log 1/C Y X Draw best possible lines through the data points on the graph
  • 23. Best line will be the one close to the data points To measure how close the data points are vertical lines are drawn from each point These verticals are measured and then scored in order to eliminate the negative values Squares are then added up to give a total Best line through the points will be the line where the total is a minimum
  • 24. The significance of the equation is know as regression coefficient(r) For a perfect fit r2=1 Good fit generally have r2 values of 0.95 or above Physiochemical properties Most commonly studied are Hydrophobic,Electrostatic and steric interaction Hydrophobic properties can easily quantified for complete molecules or for individual substituents
  • 25. Electronic and steric properties are more difficult to quantify,and quantifications are only feasible for individual substituents QSAR studies are being carried out on compounds of the same general structure where substituents on aromatic rings or accessible functional groups are varied QSAR studies then considers how the hydrophobic,electronic,and steric properties of the substituents affect the biological activity
  • 26. Hydrophobicity How easily it crosses the cell membranes and may well also be important in receptor interactions Changing substituents on a drug may well have significant effects on its hydrophobic character and hence its biological activity P= Concentration of the drug in octonol Concentration of drug in aqueous solution
  • 27. Hydrophobic compounds - P-values hydrophilic compounds - low P values Biological activity = 1/C C=Concentration of the drug required to achieve a defined level of biological activity If Log P values is resticted to a small range (1-4) a straight line graph is obtained showing that there is a relation ship between hydrophobicity and biological activity Log(1/C)=K1 log P+k2
  • 28. Increasing the hydrophobicity of a lead compound results in a increase in biological activity Compounds having a log P value close to 2 should be capable of entering the central nervous system effectively Drugs which are designed to act elsewhere in the body should have lop values significantly different from 2 in order to avoid possible central nervous system
  • 29. Substituent Hydrophobicity constant Measure of how hydrophobic a substituent is relative to hydrogen πx = log Px - log PH PH-partition coefficient of a standard compound Px-partition coefficient of a standard compound with substituent +value –Substituent is more hydrophobic -value - Substituent is less hydrophobic
  • 30. The electronic effects of various substituents will clearly have an effect on drugs ionisation or polarity Measured in terms of Hammet substituent constant σ σ-measure of electronic with drawing or electron donating ability of a substituent Determined by measuring the ability of a series of substituted benzoic acids compared to the dissociation of benzoic acid itself Cl, CN, CF3 –σ values positive (Electron withdrawing) Me ethyl and butyl – σ –values (electron donating) Values also depend whether the subsituent is meta or or para
  • 31. σ values cant be measured for ortho substituents since such substituents have an important steric as well as electronic effects Electron withdrawing groups increase the rate of hydrolysis and have positive values Steric properties Bulk ,size,and shape of the drug may have influence on this process Tafts steric factor Molar refractivity-measure of volume occupied by an atom or group of atoms
  • 32.
  • 33.
  • 34.  
  • 36.
  • 37.
  • 38.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44.
  • 45.
  • 46. Comparision of different statistical analysis r^2=correlation coefficient .856 .739 2 .798 .013 9.26 .910 .839 2 .795 .0168 6.26 .839 .793 2 .845 .002 10.56 R^2 XVR^2 Outliers BSR^2 BSR^2ERROR PRESS 2D QSAR RSA MFA Statistical parameters
  • 47.
  • 48.
  • 49.
  • 50.
  • 51. Pretein scffold with ligand docked at active site
  • 52. The docked molecule in space filled model Ligand
  • 53. Docking scores of the ligand in the active site of human leukocyte elastase
  • 54.
  • 55. LIGAND INTERACTING WITH THE STATED AMINOACIDS IN THE ACTIVE SITE
  • 56.
  • 57.